Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | GLS | O94925 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11022943 | 0.87 | HDAC1 (0.65) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL968090 | 0.85 | POLB (0.59) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6496853 | 0.85 | POLB (0.59) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6210356 | 0.84 | CNR2 (0.52) | POLBUSP2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15831226 | 0.84 | POLB (0.58) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18089044 | 0.84 | HDAC1 (0.62) | RAB9AGAA | |
| SCHEMBL8351647 | 0.84 | FFAR1 (0.60) | POLBUSP2ALDH1A1HTTGAA | |
| SCHEMBL31249652 | 0.83 | SMN1; SMN2 (0.61) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL378705 | 0.83 | SMN1; SMN2 (0.61) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2748652 | 0.83 | POLB (0.56) | POLBUSP2ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | POLB 3654/4885USP2 1598/4885ALDH1A1 867/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | POLB 3655/4885USP2 3577/4885ALDH1A1 3573/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | POLB 1670/4885USP2 685/4885ALDH1A1 3496/4885 |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | POLB 3654/4885USP2 1598/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.